Biogen Q2 Preview: Can It Change The Narrative After Q1 Strength Was Overshadowed?

Despite 11% sales growth during the first quarter, Biogen faces pessimism about continuing to pursue the amyloid hypothesis in Alzheimer’s and competitive threats to Spinraza and Tecfidera. ALS and biosimilars may offer upside.